Preclinical Development – Biomolecular
2019 PharmSci 360
The term bispecific antibody (bsAb) is used to describe a large family of molecules designed to recognize two different epitopes or antigens. Landmark advances in the engineering and development of bsAbs are enabling unprecedented versatility in therapeutic antibody concepts. Currently more than 20 different commercialized technology platforms are available for bsAb creation and development, two bsAbs are marketed and over 85 are in clinical development. A defining bsAb feature is their potential for novel functionalities — that is, activities that do not exist in mixtures of the parental or reference antibodies. This presentation will provide insights in the design and function of these so-called obligate bsAb and their potential in drug development.